Gå til innholdet

External collaboration

To nurture innovation across our value chain we work through an extensive global network within the aquaculture business and in close cooperation with various local scientific institutes, authorities, fish farmers and fish health personnel. For us, this is an important contribution to idea creation and the best utilization of resources, yielding a unique basis for development and supply of excellent products to existing and new markets.

We are always open for new partners and proposals to join our way to make aquaculture progress.

External funded R&D projects, ongoing:

Improved vaccines against intracellular pathogens in aquaculture - combining PHARMAQ and Isconova technology
- The project is funded by Eurostars - E!5934 New-Vac.                                                                 

Et flerfaglig prosjekt for å forbedre badebehandling mot lakselus (Topilouse)
- Fiskeri- og havbruksnæringens forskningsfond (FHF) 900466 (2010-2011)

Identifikasjon av ukjente sykdomsagens.
- Norwegian Research council, 200511 (2010-2011).

Indo-Norwegian platform on fish and shellfish vaccine Development.
- Norwegian Research council 183205/S40 Havbruksprogrammet (2008-2011)

A combinatorial mutagenesis approach to improve microbial expression systems.
- Norwegian Research council 182627 (2008-2010).

Intracellular lifestyle of Francisella piscicida in Atlantic cod.
-Norwegian Research council (2010-2013)

External funded R&D projects, closed:

Development of a vaccine for the Korean flat fish aquaculture industry.
- Innovation Norway, IFU 2010

Training in connection with establishment in Vietnam.
- NORAD (2009-2011)

Påvirker avlsarbeidet for økt sjukdomsresistens forekomsten av vaksineskader, immunrespons og effekten av vaksinering?
- Nofima (2007-2010) 

Immunity of Aquatic Animals - IMAQUANIM. 
- 22 partners in Europe, including NVH, NFH and PHARMAQ (2005-2010)

Utvikling av en real time PCR metode for kvantifisering av ILA virus.
- MABIT (2010)

Bilateral cooperation on fish vaccine development for Chinese aquaculture.
- BILAT 190339 (2009)

Heart and Skeletal Muscle Inflammation (HSMI) - molecular characterisation of the virus and vaccine development.
- Fuge 176975 (2006-2009).

Characterisation of Piscirikettsia salmonis, infection and technology development for optimal vaccines against intracellular bacteria. 
- Fuge 180208 (2007-2009).

Vaccines for the catfish (Pangasius sp.) industry in Vietnam.
- IFU project, development of vaccines to the industry in Vietnam (2006-2009).

Characterization of Francisella piscicida infection in Atlantic cod cells.
- MABIT. Two partners, including PHARMAQ (2009)

> Learn more about our value chain


Samples from diseased fish of a variety of species of different geographical origin are sent directly to our dedicated team of bacteriologists and virologists in R&D for cultivation and characterization. At this stage, the key to success is the joint efforts of our PHARMAQ field force in different regions of the world and cooperation with our external partners including various scientific institutes, fish farmers and fish health personnel.

Cultivation and characterization of virus and bacteria challenge our R&D people. In some cases it even results in identification of previous uncharacterized pathogens.

PHARMAQ actively utilizes IPR actively to secure freedom to operate and to create value and competitive advantages. Several patents and patent applications covering future products and technologies are held by the company.

Research & Development

Identifying the best solutions to our customers' needs for new vaccines and fish health products, requires dedicated and targeted R&D efforts. Effective vaccine solutions to different bacterial and viral diseases depend upon extensive research and development and a broad range of competencies and highly equipped technical facilities.

The causative pathogen for a disease is usually already known before we start development of new vaccine component. Challenges lies in the ability to identify and characterize the best protective antigens, how to produce them and to optimize the way in which the antigens are presented to the fish in order to obtain protection against disease.

The rate of success of introducing new products and development of efficient processes is founded on the firm commitment to re-invest in R&D and related competencies in the PHARMAQ value chain.

Documentation and registration

Documentation requirements for new products are strictly regulated. Through all steps of research, development and product testing the interaction with the PHARMAQ regulatory department is essential in establishing high quality product documentation for different regulatory bodies around the world.

Our vaccines and therapeutics hold veterinary medicinal product licenses in each country in which they are sold. These licenses certify to the quality, safety, efficacy and environmental effects of each product in the local environment.


All PHARMAQ's vaccines are manufactured at our well recognized facility at Overhalla in Norway. Specific diseases in different farmed fish species and regions need separate vaccine and therapeutic solutions. Careful production planning and logistics combined with flexibility, new ideas and core competencies in vaccine manufacturing make this possible.

Quality is documented in every step from preparation of seed material to final product and throughout the product life cycle. Our quality system ensures that the defined product is manufactured and tested the same way every time, securing that the final product meets the requirements regarding quality, safety and efficacy. The final products are released by a Qualified Person (QP), approved by the authorities. As a pharmaceutical company we are frequently inspected by different national regulatory authorities in order to prove our standards.

Customer Service

By providing environmentally sound, safe and efficacious health products and services to our global aquaculture customers, we will continue to meet our main objective namely to be selected by our customers as their preferred supplier and partner. We put pride in being flexible and create customer satisfaction through high quality service and products.

We can only be successful in this effort if our customers produce predictable yields and healthy profits.

PHARMAQs Pharmacovigilance system is an integral part of post marketing activities in the field of veterinary medicinal products.

Did you know...

We allocate around 18% of our revenue to research and development to provide environmentally sound, safe and efficacious products for the aquaculture industry.


Head office/
Production facility
Skogmo Industriområde
Industrivegen 50
N-7863 Overhalla, Norway
Tel:+47 74 28 08 00

Production facility
Dyrskuevien 13, 2040 Kløfta
P.O.Box 152, N-2041 Kløfta, Norway
Tel: +47 23 29 85 00


Harbitzalléen 2A, 0275 Oslo
P.O.Box 267 Skøyen
N-0213 Oslo, Norway
Tel: +47 23 29 85 00


PHARMAQ Analytiq
Thormøhlensgate 53D
N-5008 Bergen, Norway
Tel: (+47) 23 29 85 00


Havneveien 6
N-8700 Nesna, Norway
Tel:+47 941 63 150


PHARMAQ AS Chile Ltda.
Bernardino # 1981, Piso 2, Oficina 202,
Parque Empresarial San Andrés,
Puerto Montt, Chile
Tel: +56 65 248 3091


United Kingdom

Unit 15 Sandleheath Industrial Estate,
Hampshire SP6 1PA,
United Kingdom
Tel: +44 1425 656081

Terms & Conditions of Purchase
Terms & Conditions of Sale
Tax strategy and Disclosure: Financial year ending 30 November 2017


PHARMAQ Veteriner Ecza Deposu ve Su Ürünleri Tic.Ltd.Şti
Tel: +90 232 422 23 10


R. 2503, 25th Fl., Viettel Tower
285 Cach Mang Thang Tom
W.12, D10, HCMC, Vietnam
Tel : +84 28 6284 5350


Zoetis Panamá / PHARMAQ Panamá
Piso 2. Oficina 108. P.H. Albrook Commercial Park
Ave. Bella Vista, Ancón, Panamá
PO. Box: 0832-0588
Phone: +507 3215363
Mob.: +507 6675 1109


PHARMAQ Spain Aqua
Avda de Europa 20B
Parque Empresarial La Moraleja
28108 Alcobendas, Spain
Tel: +34 91 419 19 35


PHARMAQ part of Zoetis
108 Pasir Panjang Road
Singapore 118535, Singapore
Tel.: +65 6933 5800

PHARMAQ is the global leader in vaccines and innovation for aquaculture and part of Zoetis, the world leader in animal health. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, Vietnam, Turkey, Spain, Panama and Hong Kong. PHARMAQ has approximately 300 employees. The company's products are marketed in Europe, North and South America, and Asia. For further information, visit the company's website at www.pharmaq.comPrivacy Policy. Cookie Policy. Terms of Use.

Copyright © 2016 Zoetis LLC. All rights reserved.

Utviklet av Imaker as